G'day all,
Excited by this announcement, will be along for the ride to see how it pans out.
I haven't digested all of the above comments, but what has sprung to mind for me is the following.
Will IHL continue to receive the 42.5% R+D rebate for research conducted in Australia if the parent company of the trial is no longer domiciled in Australia?